Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood.

Cancelas JA, Rugg N, Fletcher D, Pratt PG, Worsham DN, Dunn SK, Marschner S, Reddy HL, Goodrich RP.

Transfusion. 2011 Jul;51(7):1460-8. doi: 10.1111/j.1537-2995.2010.03027.x. Epub 2011 Jan 28.

PMID:
21275998
2.

Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons.

Goodrich RP, Murthy KK, Doane SK, Fitzpatrick CN, Morrow LS, Arndt PA, Reddy HL, Buytaert-Hoefen KA, Garratty G.

Transfusion. 2009 Jan;49(1):64-74. doi: 10.1111/j.1537-2995.2008.01940.x. Epub 2008 Oct 14.

PMID:
18954398
3.

Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at -30 degrees C.

Bihm DJ, Ettinger A, Buytaert-Hoefen KA, Hendrix BK, Maldonado-Codina G, Rock G, Giclas PC, Goodrich RP.

Vox Sang. 2010 Feb;98(2):108-15. doi: 10.1111/j.1423-0410.2009.01238.x. Epub 2009 Aug 30.

PMID:
19719460
4.

Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2 years at -30 °C.

Ettinger A, Miklauz MM, Hendrix BK, Bihm DJ, Maldonado-Codina G, Goodrich RP.

Transfus Apher Sci. 2011 Feb;44(1):25-31. doi: 10.1016/j.transci.2010.12.005. Epub 2011 Jan 19.

PMID:
21251884
5.

Protein quality in Mirasol pathogen reduction technology-treated, apheresis-derived fresh-frozen plasma.

Smith J, Rock G.

Transfusion. 2010 Apr;50(4):926-31. doi: 10.1111/j.1537-2995.2009.02517.x. Epub 2009 Dec 29.

PMID:
20051060
6.

The Mirasol Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution.

Reikvam H, Marschner S, Apelseth TO, Goodrich R, Hervig T.

Blood Transfus. 2010 Jul;8(3):186-92. doi: 10.2450/2010.0141-09.

7.

Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation.

Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP.

Transfus Med Rev. 2008 Apr;22(2):133-53. doi: 10.1016/j.tmrv.2007.12.003. Review.

PMID:
18353253
8.

Pathogen reduction of fresh plasma using riboflavin and ultraviolet light: effects on plasma coagulation proteins.

Hornsey VS, Drummond O, Morrison A, McMillan L, MacGregor IR, Prowse CV.

Transfusion. 2009 Oct;49(10):2167-72. doi: 10.1111/j.1537-2995.2009.02272.x. Epub 2009 Jun 23.

PMID:
19555414
9.

Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction.

AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, Edrich R, Goodrich RP.

Transfusion. 2005 Aug;45(8):1335-41.

PMID:
16078923
10.

In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days.

Cookson P, Thomas S, Marschner S, Goodrich R, Cardigan R.

Transfusion. 2012 May;52(5):983-94. doi: 10.1111/j.1537-2995.2011.03388.x. Epub 2011 Oct 20.

PMID:
22014032
11.

White blood cell inactivation after treatment with riboflavin and ultraviolet light.

Marschner S, Fast LD, Baldwin WM 3rd, Slichter SJ, Goodrich RP.

Transfusion. 2010 Nov;50(11):2489-98. doi: 10.1111/j.1537-2995.2010.02714.x. Review.

PMID:
20529002
12.

Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products.

Goodrich RP, Doane S, Reddy HL.

Biologicals. 2010 Jan;38(1):20-30. doi: 10.1016/j.biologicals.2009.10.016. Epub 2010 Jan 25.

PMID:
20093041
13.

Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method.

Schubert P, Culibrk B, Karwal S, Serrano K, Levin E, Bu D, Bhakta V, Sheffield WP, Goodrich RP, Devine DV.

Transfusion. 2015 Apr;55(4):815-23. doi: 10.1111/trf.12895. Epub 2014 Oct 29.

PMID:
25355434
14.

Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.

Ambruso DR, Thurman G, Marschner S, Goodrich RP.

Transfusion. 2009 Dec;49(12):2631-6. doi: 10.1111/j.1537-2995.2009.02347.x. Epub 2009 Aug 18.

PMID:
19694996
15.

Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution.

Picker SM, Tauszig ME, Gathof BS.

Transfusion. 2012 Mar;52(3):510-6. doi: 10.1111/j.1537-2995.2011.03323.x. Epub 2011 Oct 7.

PMID:
21981030
16.

Cell viability during platelet storage in correlation to cellular metabolism after different pathogen reduction technologies.

Picker SM, Schneider V, Oustianskaia L, Gathof BS.

Transfusion. 2009 Nov;49(11):2311-8. doi: 10.1111/j.1537-2995.2009.02316.x. Epub 2009 Jul 16.

PMID:
19624608
17.

Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment.

Jackman RP, Heitman JW, Marschner S, Goodrich RP, Norris PJ.

Transfusion. 2009 Dec;49(12):2686-99. doi: 10.1111/j.1537-2995.2009.02333.x. Epub 2009 Aug 4.

18.

Pathogen-reduction systems for blood components: the current position and future trends.

Seghatchian J, de Sousa G.

Transfus Apher Sci. 2006 Dec;35(3):189-96. Epub 2006 Nov 15. Review.

PMID:
17110168
19.

Hemolysis of human red blood cells by combination of riboflavin and aminophylline.

Ali L, Naseem I.

Life Sci. 2002 Mar 15;70(17):2013-22.

PMID:
12148693
20.

Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology.

Ostrowski SR, Bochsen L, Windeløv NA, Salado-Jimena JA, Reynaerts I, Goodrich RP, Johansson PI.

Transfusion. 2011 Feb;51(2):344-56. doi: 10.1111/j.1537-2995.2010.02821.x. Epub 2010 Aug 16.

PMID:
20723169
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk